Kansas Intellectual and Developmental Disabilities Research Center
Welcome to the Kansas Intellectual and Developmental Disabilities Research Center (KIDDRC) web site. The mission of the KIDDRC is to support high quality basic and applied research relevant to the causes and prevention of intellectual and developmental disabilities. We also support research aimed at the prevention and remediation of some of the many secondary conditions associated with intellectual and developmental disabilities, such as difficulty in language acquisition and behavior problems.
For over four decades our Center, in partnership with the Eunice K. Shriver National Institute of Child Health and Human Development and other federal agencies, has played a major role in generating effective behavioral interventions aimed at the causes, prevention, and treatment for intellectual and related developmental disabilities, and in delineating basic knowledge of the underlying biology of typical and atypical development. We have accomplished this by uniting researchers and clinicians in a common effort at three critical sites within the state of Kansas: the University of Kansas in Lawrence, Juniper Gardens Children's Project; and the University of Kansas Medical Center in Kansas City.
— Peter Smith, Co-Director; John Colombo, Director
1/16/13 KIDDRC Co-Director Peter Smith and colleagues, including KIDDRC member Hinrich Staecker, published in the January 2013 Journal of Neuroscience their findings that “bone morphogenetic protein 4 (BMP4), an important factor in early nervous system development and regeneration after injury, is a critical mediator of adult physiological plasticity as well. 2/28/13 Update: KUMC news release.
1/11/13 Navneet K. Dhillon and colleagues report new findings supporting the multiple-hit
mechanism of illicit drug use on pulmonary arterial hypertension and speculate that the consumption of illicit drugs render HIV-infected individuals more susceptible to the occurrence of PAH.
1/11/13 Joseph Moskovitz 's patent application for the development of novel antibodies that can recognize Methionine sulfoxide protetins was approved in December 2012 and expected to be issued in March 2013.
The major research and office locations of the KiDDRC. Clockwise: Robert E. Hemenway Life Sciences Innovation Center (2008), the The Robert Dole Human Development Center (1990) and the Children's Campus of Kansas City (2010)
Supported by the Kansas IDDRC, P30 NICHD HD 002528